DEXCOM INC. - 10-Q Filing Summary
Business Context and Reporting Period
Company: DexCom, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: DexCom is a medical device company focused on continuous glucose monitoring (CGM) systems for diabetes management. Key products include the G6, G7, and the over-the-counter Stelo biosensor. The company operates as a single reportable segment globally.
Key Financial Metrics (Three Months Ended Sept 30, 2025)
| Metric | Q3 2025 | Q3 2024 | YoY Change |
|---|---|---|---|
| Revenue | $1,209.3 million | $994.2 million | +22% |
| Gross Profit | $731.4 million | $593.8 million | +23% |
| Gross Margin | 60.5% | 59.7% | +80 bps |
| Operating Income | $242.5 million | $152.0 million | +60% |
| Net Income | $283.8 million | $134.6 million | +111% |
| Diluted EPS | $0.70 | $0.34 | +106% |
| Operating Cash Flow (9mo) | $1,146.7 million | $688.1 million | +67% |
Liquidity & Balance Sheet (as of Sept 30, 2025):
- Cash & Equivalents: $1,835.7 million
- Short-term Marketable Securities: $1,486.4 million
- Total Liquid Assets: $3.32 billion
- Debt: $2.45 billion principal in senior convertible notes ($1.21 billion due Nov 2025; $1.25 billion due May 2028).
- Working Capital Ratio: 1.56
Material Changes vs. Prior Period
- Revenue Growth: Driven by increased sales volume of disposable sensors and a net addition of 500,000–600,000 customers in 2024. Growth was partially offset by pricing headwinds from rebates and channel mix.
- Profitability Surge: Net income more than doubled, aided by a significant $82.7 million gain on equity investments included in "Other income, net."
- Expense Management: SG&A expenses increased due to higher compensation and marketing, but were offset by a $26.8 million reduction in legal expenses following the settlement of a patent infringement lawsuit in December 2024.
- Tax Rate: Effective tax rate for the nine months ended Sept 30, 2025, was 23.9%, influenced by share-based compensation shortfalls and a tax benefit from the commencement of a Malaysia tax holiday.
Guidance, Outlook, Risks, and Unusual Items
- Debt Maturity: $1.21 billion in 2025 Senior Convertible Notes matures on November 15, 2025. Management intends to repay this in cash.
- Regulatory Risk (FDA Warning Letter): In March 2025, DexCom received an FDA warning letter regarding deficiencies in manufacturing processes and quality management systems at San Diego and Mesa facilities. While not currently restricting production, failure to resolve these issues could lead to recalls or production shutdowns.
- Legal Proceedings: Ongoing securities class action litigation regarding alleged false statements on revenue and growth potential (filed late 2024/early 2025) and a new class action filed in October 2025 regarding G7 device accuracy. Derivative actions are also pending.
- Share Repurchases: In Q3 2025, the company repurchased 2.4 million shares for $187.2 million under a $750 million program authorized in April 2025.
- Unusual Items: The "Other income, net" line item includes $82.7 million in net gains on equity investments, significantly boosting net income for the quarter.
Investor Verification Checklist
- Debt Refinancing: Verify the company's plan and liquidity sufficiency to repay the $1.21 billion note maturing in November 2025.
- FDA Resolution: Monitor the status of the corrective action plan submitted to the FDA regarding the March 2025 warning letter.
- Legal Exposure: Track the progress of the securities class action lawsuits and potential settlement costs.
- Revenue Quality: Assess the sustainability of revenue growth given the noted pricing headwinds and rebate eligibility pressures.
- Equity Gains: Determine the recurring nature of the $82.7 million gain on equity investments to normalize earnings expectations.